Ruben Dario Vasquez Becerra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruben Dario Vasquez Becerra has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Augusto Yabar
Universidad de San Martín de Porres
2 shared publications - Carlos Benites
Ministerio de Salud Lima Peru
2 shared publications - Adolfo Marcelo
National Reference Laboratory for Vector-borne and Viral Zoonotic Diseases, National Institute of Health, Lima, Peru
1 shared publication - Ana Vera
Equipo Técnico - Dirección de Prevención y Control de VIH/ITS/Hepatitis – Ministerio de Salud, Lima, Perú
1 shared publication - Angélica Victoria García Tello
Universidad Nacional de Trujillo
1 shared publication - César Ramal Asayag
Faculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 43 (1) , 104-9
Coinfección viral con SARS-CoV2 en pacientes peruanos hospitalizados durante los años 2020-2021
El estudio tuvo como objetivo identificar las coinfecciones de SARS-CoV-2 con otros virus en pacientes con COVID-19 moderada y grave. Se seleccionaron 98 pacientes de Lima, San Martín y Loreto, a quienes se tomaron muestras de secreción nasofaríngea, sangre y orina analizadas mediante pruebas serológicas y moleculares para detectar HTLV, VIH, hepatitis B, dengue, Chikungunya, Zika y un panel de virus respiratorios (influenza A/B, rinovirus, virus respiratorio sincitial, metaneumovirus y adenovirus). Los resultados mostraron dos casos de coinfección (2/98; 2%): uno con SARS-CoV-2/rinovirus y otro con SARS-CoV-2/HTLV-2. Ambos pacientes presentaron neumonía asociada a COVID-19, pero evolucionaron favorablemente. Se concluye que la frecuencia de coinfección viral en pacientes de establecimientos de salud de la costa y selva peruana con cuadros moderados y graves de COVID-19 fue baja.
- 27 March 2026
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 43 (1) , 104-9
Open AccessCoinfección viral con SARS-CoV2 en pacientes peruanos hospitalizados durante los años 2020-2021
El estudio tuvo como objetivo identificar las coinfecciones de SARS-CoV-2 con otros virus en pacientes con COVID-19 moderada y grave. Se seleccionaron 98 pacientes de Lima, San Martín y Loreto, a quienes se tomaron muestras de secreción nasofaríngea, sangre y orina analizadas mediante pruebas serológicas y moleculares para detectar HTLV, VIH, hepatitis B, dengue, Chikungunya, Zika y un panel de virus respiratorios (influenza A/B, rinovirus, virus respiratorio sincitial, metaneumovirus y adenovirus). Los resultados mostraron dos casos de coinfección (2/98; 2%): uno con SARS-CoV-2/rinovirus y otro con SARS-CoV-2/HTLV-2. Ambos pacientes presentaron neumonía asociada a COVID-19, pero evolucionaron favorablemente. Se concluye que la frecuencia de coinfección viral en pacientes de establecimientos de salud de la costa y selva peruana con cuadros moderados y graves de COVID-19 fue baja.
- 27 December 2022
- Published by Wiley in HIV Medicine
- Vol. 24 (5) , 620-627
HIV treatment cascade in regions of Peru with the highest HIV prevalence
Objectives: To describe the HIV treatment cascade and care continuum in regions of highest HIV prevalence in Peru.Methods: An observational longitudinal study was carried out in 14 tertiary hospitals in Peru. These are the main hospitals that administer antiretroviral treatment (ART) in the regions that represent approximately 95% of reports of HIV/AIDS cases in Peru in 2013. We included individuals older than 18 years newly diagnosed with HIV from 1 January 2011 to 31 December 2012. Medical records were reviewed until 2015.Results: A total of 2119 people living with HIV (PLHIV) were identified in the selected health facilities (mean age = 35.26 years, 78% male). 97.25% [1845/1897; 95% confidence interval (CI): 96.4–97.9%] of the patients attended the consultation at least once during the follow‐up, but only 64.84% (885/1365; 95% CI: 62.2–67.4%) attended within a month after the diagnosis. After starting ART, 74.63% (95% CI: 71.9–77.2%) of PLHIV remained in healthcare. Regardless of the time after diagnosis, 88.40% (1837/2078; 95% CI: 86.9–89.7%) of PLHIV started ART during the observation time. However, 78.68% (95% CI: 76.8–80.4%) did so during the first post‐treatment year and only 28.88% (95% CI: 27.9–31.9%) after 1 month. After starting treatment, it was observed that 51.60% (95% CI: 49.2–54%) of PLHIV reached viral suppression during the follow‐up period.Conclusions: Further analysis and improvements in the definition of indicators are required to achieve conclusive results; however, these data will give us a general understanding of the progress of Peruvian health policies in achieving the goal established by the WHO.
- 27 December 2022
- Published by Wiley in HIV Medicine
- Vol. 24 (5) , 620-627
HIV treatment cascade in regions of Peru with the highest HIV prevalence
Objectives: To describe the HIV treatment cascade and care continuum in regions of highest HIV prevalence in Peru.Methods: An observational longitudinal study was carried out in 14 tertiary hospitals in Peru. These are the main hospitals that administer antiretroviral treatment (ART) in the regions that represent approximately 95% of reports of HIV/AIDS cases in Peru in 2013. We included individuals older than 18 years newly diagnosed with HIV from 1 January 2011 to 31 December 2012. Medical records were reviewed until 2015.Results: A total of 2119 people living with HIV (PLHIV) were identified in the selected health facilities (mean age = 35.26 years, 78% male). 97.25% [1845/1897; 95% confidence interval (CI): 96.4–97.9%] of the patients attended the consultation at least once during the follow‐up, but only 64.84% (885/1365; 95% CI: 62.2–67.4%) attended within a month after the diagnosis. After starting ART, 74.63% (95% CI: 71.9–77.2%) of PLHIV remained in healthcare. Regardless of the time after diagnosis, 88.40% (1837/2078; 95% CI: 86.9–89.7%) of PLHIV started ART during the observation time. However, 78.68% (95% CI: 76.8–80.4%) did so during the first post‐treatment year and only 28.88% (95% CI: 27.9–31.9%) after 1 month. After starting treatment, it was observed that 51.60% (95% CI: 49.2–54%) of PLHIV reached viral suppression during the follow‐up period.Conclusions: Further analysis and improvements in the definition of indicators are required to achieve conclusive results; however, these data will give us a general understanding of the progress of Peruvian health policies in achieving the goal established by the WHO.
- Open Access
- 19 September 2022
- Published by Colegio Medico del Peru in ACTA MEDICA PERUANA
- Vol. 39 (3)
Discutiendo estrategias para la continuidad en la atención de PVV en el contexto de la pandemia por SARS CoV 2
- 19 September 2022
- Published by Colegio Medico del Peru in ACTA MEDICA PERUANA
- Vol. 39 (3)
Open AccessDiscutiendo estrategias para la continuidad en la atención de PVV en el contexto de la pandemia por SARS CoV 2